MA30322B1 - Promedicaments ameliores d'analogues de cc-1065 - Google Patents

Promedicaments ameliores d'analogues de cc-1065

Info

Publication number
MA30322B1
MA30322B1 MA31261A MA31261A MA30322B1 MA 30322 B1 MA30322 B1 MA 30322B1 MA 31261 A MA31261 A MA 31261A MA 31261 A MA31261 A MA 31261A MA 30322 B1 MA30322 B1 MA 30322B1
Authority
MA
Morocco
Prior art keywords
prodrugs
prodrug
analogues
cytotoxic
protecting group
Prior art date
Application number
MA31261A
Other languages
English (en)
Inventor
Robert Zhao
Ravi Chari
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30322B1 publication Critical patent/MA30322B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROMÉDICAMENTS AMÉLIORÉS D'ANALOGUES DE CC-1065 la présente invention concerne des promédicaments d'analogues de l'antibiotique anticancéreux CC-1065 ayant un groupe protecteur clivable contenant un phénylcarbamate contenant un acide sulfonique, dans lesquels le groupe protecteur confère une hydrosolubilité améliorée au promédicament, et dans lesquels le promédicament comporte en outre un fragment, tel qu'un sulfure ou un disulfure, qui peut se conjuguer à un réactif de liaison cellulaire tel qu'un anticorps. L'utilisation thérapeutique de tels conjugués de promédicament est également décrite ; de tels promédicaments d'agents cytotoxiques ont une utilité thérapeutique parce qu'ils peuvent délivrer des promédicaments cytotoxiques à une population de cellules spécifique pour conversion enzymatique en médicaments cytotoxiques de manière ciblée.
MA31261A 2006-03-07 2008-09-29 Promedicaments ameliores d'analogues de cc-1065 MA30322B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06290379A EP1832577A1 (fr) 2006-03-07 2006-03-07 Promédicament amélioré d'analogues de CC-1065

Publications (1)

Publication Number Publication Date
MA30322B1 true MA30322B1 (fr) 2009-04-01

Family

ID=36679356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31261A MA30322B1 (fr) 2006-03-07 2008-09-29 Promedicaments ameliores d'analogues de cc-1065

Country Status (18)

Country Link
US (2) US8012978B2 (fr)
EP (2) EP1832577A1 (fr)
JP (1) JP2009529030A (fr)
KR (1) KR20080106919A (fr)
AR (1) AR059767A1 (fr)
AU (1) AU2007222123A1 (fr)
BR (1) BRPI0708654A2 (fr)
CA (1) CA2642870A1 (fr)
DO (1) DOP2007000041A (fr)
EA (1) EA200870327A1 (fr)
IL (1) IL193673A0 (fr)
MA (1) MA30322B1 (fr)
MX (1) MX2008011431A (fr)
NO (1) NO20083910L (fr)
PE (1) PE20080691A1 (fr)
TW (1) TW200813028A (fr)
UY (1) UY30190A1 (fr)
WO (1) WO2007102069A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CA2680854C (fr) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20090155289A1 (en) * 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
ES2647317T3 (es) 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
PT3056203T (pt) * 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
AU2013239962B9 (en) 2012-03-30 2017-11-16 The Scripps Research Institute Cyclic prodrugs of duocarmycin analogs
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
CA2891280C (fr) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
RU2680404C2 (ru) 2014-01-10 2019-02-21 Синтон Байофармасьютикалс Б. В. Способ очистки cys-связанных конъюгатов антитело-лекарственное средство
CA2935433C (fr) 2014-01-10 2019-04-02 Synthon Biopharmaceuticals B.V. Conjugues anticorps-medicament anti-her2 de duocarmycine ayant une activite contre les neoplasmes malins exprimant her2
RU2686085C2 (ru) 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
WO2017197045A1 (fr) 2016-05-11 2017-11-16 Movassaghi Mohammad Synthèse totale convergente et énantiosélective d'analogues de la communesine
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4126833A1 (fr) * 2020-03-23 2023-02-08 Helmholtz-Zentrum für Infektionsforschung GmbH Dérivés de n-phényl-3-mercaptopropanamide en tant qu'inhibiteurs de métallo-bêta-lactamase pour le traitement d'infections bactériennes
WO2022182415A1 (fr) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
EP0563475B1 (fr) * 1992-03-25 2000-05-31 Immunogen Inc Conjugués d'agents ciblés et de dérivés du CC-1065
US5646298A (en) * 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs

Also Published As

Publication number Publication date
MX2008011431A (es) 2008-09-22
CA2642870A1 (fr) 2007-09-13
IL193673A0 (en) 2009-05-04
US8012978B2 (en) 2011-09-06
EP1832577A1 (fr) 2007-09-12
AR059767A1 (es) 2008-04-30
JP2009529030A (ja) 2009-08-13
NO20083910L (no) 2008-12-01
EP1993999A1 (fr) 2008-11-26
AU2007222123A1 (en) 2007-09-13
TW200813028A (en) 2008-03-16
US20110280890A1 (en) 2011-11-17
US20090028821A1 (en) 2009-01-29
KR20080106919A (ko) 2008-12-09
DOP2007000041A (es) 2007-10-31
BRPI0708654A2 (pt) 2011-06-07
EA200870327A1 (ru) 2009-02-27
WO2007102069A1 (fr) 2007-09-13
UY30190A1 (es) 2008-10-31
PE20080691A1 (es) 2008-06-04

Similar Documents

Publication Publication Date Title
MA30322B1 (fr) Promedicaments ameliores d'analogues de cc-1065
DK1492526T3 (da) Konjugerede prodrugs af CC-1065-analoger
WO2005007197A3 (fr) Molecules biologiques conjuguees et leur preparation
MA30026B1 (fr) Compositions insecticides d'efficacite accrue
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
PT1075282E (pt) Conjugados analogos de peg-lhrh
CA2235721A1 (fr) Lipopolymamines comme agents de transfection et leurs applications pharmaceutiques
MA34340B1 (fr) Composes heteroaryles contenant de l'azote
TR200401739T4 (tr) Persikuinnin, üretimi ve ilaç olarak kullanımı için bir işlem
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
WO2002038105A3 (fr) Nouveaux conjugues d'acide amine et d'analogues de polyamine utiles en tant qu'agents anticancer
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
ATE416252T1 (de) Chemisch veränderte, lipolytische enzyme
MA32170B1 (fr) Nouveaux derives d'aminomethylbenzene
WO2004037784A3 (fr) Pyrrolidones ayant une activité anti-vih
Matsumoto et al. ‘Double-drugs’—A new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker
WO2002007770A3 (fr) Conjugues polymeres d'agents antitumoraux
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
ATE317695T1 (de) Parenterale lösung enthaltend amiodaron
AU3642701A (en) Hydrolytic enzyme substrates and assay method
TR200002972T2 (tr) 1-dezoksi-D-ksiluloz-5-fosfat biyosentez yolunun engellenmesi için aktif maddeler ve kimyasal aktif maddelerin belirlenmesi için işlem
IT1318547B1 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.